SOA Wealth Advisors LLC. Has $32,000 Stock Holdings in GSK PLC Sponsored ADR $GSK

SOA Wealth Advisors LLC. increased its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 252.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 845 shares of the pharmaceutical company’s stock after acquiring an additional 605 shares during the quarter. SOA Wealth Advisors LLC.’s holdings in GSK were worth $32,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Dodge & Cox lifted its stake in shares of GSK by 14.9% during the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after acquiring an additional 10,210,921 shares during the period. Primecap Management Co. CA lifted its stake in GSK by 1.8% in the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock valued at $995,929,000 after buying an additional 446,360 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in GSK by 2.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock valued at $299,163,000 after buying an additional 155,392 shares during the period. Royal Bank of Canada lifted its stake in GSK by 5.7% in the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock valued at $293,692,000 after buying an additional 411,869 shares during the period. Finally, Equity Investment Corp lifted its stake in GSK by 5.3% in the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company’s stock valued at $161,708,000 after buying an additional 211,608 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on GSK shares. Weiss Ratings reissued a “hold (c)” rating on shares of GSK in a research note on Saturday, September 27th. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Seven equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $37.38.

GSK Stock Down 0.9%

NYSE:GSK opened at $43.30 on Friday. The company has a market cap of $88.10 billion, a PE ratio of 20.05, a PEG ratio of 2.17 and a beta of 0.53. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $45.59. The stock has a 50-day simple moving average of $39.76 and a 200 day simple moving average of $38.70. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a dividend yield of 3.9%. The ex-dividend date is Friday, August 15th. GSK’s payout ratio is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.